

## **TEST CHANGE**

| 17-Hydroxypregnenolone Baseline Specimen<br>0092335, OHPRGNBASE |  |  |
|---|--|--|
| Specimen Requirements:  |  |  |
| Patient Preparation:  |  |  |
| Collect:  | Serum separator tube. Also acceptable: Plain red, lavender (EDTA), pink (K2EDTA), or green (sodium or lithium heparin).  |  |
| Specimen Preparation:   | Separate serum or plasma from cells ASAP or within 2 hours of<br>collection. Transfer 0.5 mL serum or plasma to an ARUP<br>Standard Transport Tube and freeze immediately. (Min: 0.25<br>mL) |  |
| Transport Temperature:  | CRITICAL FROZEN. Separate specimens must be submitted when multiple tests are ordered.   |  |
| Unacceptable Conditions:  | Refrigerated or room temperature specimens.  |  |
| Remarks:  |  |  |
| Stability:  | After separation from cells: Ambient: Unacceptable;<br>Refrigerated: Unacceptable; Frozen: 6 months  |  |
| Methodology:  | Quantitative High Performance Liquid Chromatography-<br>Tandem Mass Spectrometry   |  |
| Performed:  | Mon-Fri  |  |
| Reported:   | 1- <u>5</u> 4 days   |  |
| Note:   |  |  |
| CPT Codes:  | 84143  |  |
| New York DOH Approval Status:                                   | This test is New York DOH approved.  |  |

Interpretive Data:

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Reference Interval:



| Age                        | Female                             | Male                               |
|----------------------------|------------------------------------|------------------------------------|
| Premature (26-28<br>weeks) | 1219-9799 ng/dL                    | 1219-9799 ng/dL                    |
| Premature (29-36<br>weeks) | 346-8911 ng/dL                     | 346-8911 ng/dL                     |
| Full Term (1-5<br>months)  | 229-3104 ng/dL                     | 229-3104 ng/dL                     |
| 6-12 months                | less than or equal<br>to 917ng/dL  | less than or equal<br>to 917ng/dL  |
| 13-23 months               | less than or equal<br>to 592 ng/dL | less than or equal<br>to 592 ng/dL |
| 2-4 years                  | less than or equal<br>to 280 ng/dL | less than or equal<br>to 249 ng/dL |
| 5-6 years                  | less than or equal<br>to 350 ng/dL | less than or equal<br>to 319 ng/dL |
| 7-9 years                  | less than or equal<br>to 212 ng/dL | less than or equal<br>to 187 ng/dL |
| 10-12 years                | less than or equal<br>to 398 ng/dL | less than or equal<br>to 392 ng/dL |
| 13-15 years                | less than or equal<br>to 407 ng/dL | 35-465 ng/dL                       |
| 16-17 years                | less than or equal<br>to 423 ng/dL | 32-478 ng/dL                       |
| 18 years and older         | Less than 226<br>ng/dL             | Less than 442<br>ng/dL             |
| Tanner Stage I             | less than or equal<br>to 235 ng/dL | less than or equal<br>to 208 ng/dL |
| Tanner Stage II            | less than or equal<br>to 367 ng/dL | less than or equal<br>to 355 ng/dL |
| Tanner Stage III           | less than or equal<br>to 430 ng/dL | less than or equal<br>to 450 ng/dL |
| Tanner Stage IV-<br>V      | less than or equal<br>to 412 ng/dL | 35-478 ng/dL                       |